Tirzepatide 12.5mg Kwikpen

Product Introduction

Tirzepatide 12.5mg KwikPen is a once-weekly injectable GIP and GLP-1 receptor agonist used in adults with type 2 diabetes and chronic weight management under an approved treatment plan. It improves glucose-dependent insulin secretion, lowers glucagon when glucose is high, slows gastric emptying, improves insulin sensitivity, and acts on appetite-regulating pathways. It is not insulin and is not used for type 1 diabetes or diabetic ketoacidosis. Tell clinicians before anesthesia or procedures because delayed stomach emptying may affect aspiration risk.

How to use

Inject Tirzepatide 12.5mg KwikPen subcutaneously once weekly exactly as trained. Rotate injection sites, follow storage and missed-dose rules, and never share pens or needles.

How it works

Tirzepatide activates GIP and GLP-1 receptors, increasing glucose-dependent insulin release, reducing glucagon, slowing gastric emptying, and reducing appetite.

Common side effects

Possible effects include nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, burping, reduced appetite, and injection-site reactions. Serious concerns include pancreatitis, gallbladder disease, kidney injury from dehydration, severe GI reactions, hypoglycemia with insulin/sulfonylureas, thyroid tumor warning, and allergy.

Important information

Review type 1 diabetes, ketoacidosis, pancreatitis, gallbladder disease, kidney disease, severe GI disease, diabetic retinopathy, thyroid cancer or MEN2 history, pregnancy plans, breastfeeding, insulin, sulfonylureas, oral contraceptives, anesthesia plans, and injection technique.